Clinical trial NCT03348527: A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
Official title: A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection Into the Prostate in Patients With Localized Prostate Cancer, Assigned to Active Surveillance Who Are at High Risk for Disease Progression (Followed by an Open Label Extension With a Repeat Injection (Optional)).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: Lidds AB
Sponsor class: INDUSTRY
Collaborators: name: CMX Research
First posted: 2017-11-21
Enrollment: 61
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Stage I: 20 Subjects will be enrolled into one of two groups, each receiving a single dose of Liproca®Depot. The target treatment dose will be 35% (Cohort 1) or 45% (Cohort 2) of the prostate volume (mL).

Stage II: 40 subjects will be randomized to receive either 16 mL (Cohort 3) or 20mL (Cohort 4) of Liproca®Depot.
Primary purpose: TREATMENT

Brief summary: A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer,Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional))

Detailed description: Patients assigned to Active Surveillance and who have fulfilled all inclusion criteria will receive a prophylactic antibiotic and a local anaesthetic (according to the Investigator's Standard of Care) prior to administration of Liproca® Depot.

60 subjects will be enrolled.

The Single Dose Study will be conducted in two stages:

In Stage I, 20 subjects will be randomized into two groups to receive one dose of Liproca® Depot equal to 35% (Cohort 1) or 45 % (Cohort 2) of their prostate volume (mL) (N=10:10). Two weeks after all subjects have received their initial dose, the Data Safety Monitoring Board (DSMB) will review the subjects' safety and tolerability data over the first 14 days after receiving treatment.

In Stage II, 40 subjects will be randomized to receive either 16mL (Cohort 3) or 20mL (Cohort 4) of Liproca® Depot.

All subjects in Stage I and Stage II will be followed for 24 weeks.

Subjects who complete the Single Dose Study and who experience no safety or tolerability issues, as determined by the Investigator, may be offered an option to participate in the Open Label Extension Study (OLE). Subjects enrolled in the OLE will be observed for PSA recurrence every 8 weeks. If PSA recurrence is confirmed (defined as a PSA level exceeding at least 100 % of Baseline value) subjects will receive a second treatment of Liproca® Depot. The dose will be injected into the tumour focus/foci and in close proximity to the tumour, based on a prostate biopsy (and MRI, if applicable), using a TRUS for guidance.

Stage I subjects who received 35% volume of Liproca® Depot will receive 16 mL and subjects who received 45% volume of Liproca® Depot will receive 20 mL. Stage II subjects will receive the same dose of Liproca® Depot that was administered in the first treatment.

Subjects in the OLE receiving a second injection will be followed up for an additional 24 weeks for safety, tolerability and efficacy. After this period, subjects may undergo MRI imaging and a prostate biopsy.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent prior to any study specific procedures being performed
* 18 - 80 years of age, inclusive
* Assigned to Active Surveillance
* Histologically confirmed, localized prostate cancer within 24 months of Screening
* Gleason score 3+3 or 3+4 with one or more of the following characteristics:

PSA \> 6.0 μg/L (ng/mL) and PSA density \> 0.15; PSA \> 10.0 μg/L and \< 20 μg/L (ng/mL); Any systematic core \> 50% involvement; Any PI-RADS score 4 or 5 on MRI; Any Gleason grade 4, Men of African descent

* Patient has a negative bone scan within the last 12 months
* Patient is able to have an MRI
* Prostate volume ≤ 80 mL (measured by MRI within 12 months of Screening or has been scheduled for an MRI prior to Screening)
* eGFR ≥ 30 mL/min, using the Cockcroft - Gault Equation: = \[{(140 - age in years) x (weight in kg)} x 1.23\] / serum Creatinine in micromol/l
* AST, ALT and ALP ≤ 1.5 times upper limit of normal
* Patient must be willing to comply with all study procedures
* Patients must agree to the use of medically acceptable methods of contraception, including non-hormonal intrauterine device (IUD) or double barrier method (condom with foam or vaginal spermicidal suppository, diaphragm with spermicide) for the duration of the study (24 weeks), unless the patient and/or their partner has been surgically sterilized

Exclusion Criteria:

* PSA \> 20 μg/L (ng/mL)
* Previous or ongoing hormonal therapy for prostate cancer
* Positive urine culture before treatment with prophylactic antibiotics
* Ongoing or previous therapy with finasteride or dutasteride in the last 3 months
* Ongoing or previous invasive therapy for benign prostate hyperplasia (BPH) (e.g. TURP,TUMT, HIFU, etc.)
* Use of pacemaker or other implanted electronic devices
* Metal implant in the pelvis (e.g. hip replacement) that may affect the MRI of the prostate
* Allergy to Liproca® Depot and its ingredients
* Severe micturition symptoms (I-PSS \>15 or residual urine volume \> 150 mL) confirmed by repeat measurement or Qmax\< 12 mL/s
* Ongoing therapy with the anticoagulant Acetyl Salicylic Acid (ASA) (more than 100mg/day) as preventive anti-thrombotic therapy should be withdrawn temporarily before treatment with Liproca® Depot, as determined by the Investigator. Other anticoagulants should be withdrawn in cooperation with the treating physician
* Use of any previous focal prostate cancer treatment, such as transurethral resection, cryotherapy, high intensity frequency ultrasound (HIFU) and/or photodynamic therapy
* Concomitant systemic treatment with corticosteroids or immune modulating agents
* Known immunosuppressive disease (e.g. HIV, Type II Diabetes). Patients with well controlled Type II Diabetes may be included, as determined by Investigator
* Simultaneous participation in any other study involving an investigational product or device,or having participated in a prostate cancer study within the last 12 months prior to starting treatment with Liproca® Depot
* Infection in WHO Risk Group 2, 3 or 4

Primary outcomes:
measure: Highest Tolerable Dose of Liproca Depot
timeFrame: 24 weeks
Secondary outcomes:
measure: Liproca Depot Effect on Prostate Specific Antigen Levels
timeFrame: 24 weeks
measure: Liproca Depot Effect on Prostate Volume
timeFrame: 20 weeks
measure: Evaluation of Lesions
timeFrame: 20 weeks
measure: Quality of Life (QoL) Questionnaire Score
timeFrame: 24 weeks
measure: Micturition Status using the International Prostate Symptom Score (I-PSS)
timeFrame: 24 weeks
measure: Frequency of Adverse Events
timeFrame: 24 weeks
measure: Change in Testosterone Levels
timeFrame: 24 weeks
measure: Systematic Exposure of 2-hydroxyflutamide
timeFrame: 24 weeks
measure: Pharmacokinetics of 2-hydroxyflutamide
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Nova Scotia Health Authority
state: Nova Scotia
city: Brampton
country: Canada
facility: Jonathan Giddens Medicine Professional Corporation
state: Ontario
city: Burlington
country: Canada
facility: G. Kenneth Jansz Medicine Professional Corporation
state: Ontario
city: Oakville
country: Canada
facility: The Fe/Male Health Centres
state: Ontario
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre
state: Ontario
city: Sherbrooke
country: Canada
facility: CIUSSS de l'Estrie - CHUS
state: Quebec
city: Helsinki
country: Finland
facility: Helsinki University Hospital
city: Tampere
country: Finland
facility: Tampere University Hospital
city: Kaunas
country: Lithuania
facility: Hospital of Lithuanian University of Health Sciences
city: Vilnius
country: Lithuania
facility: National Cancer Institute - Oncourology Department
Study officials:
affiliation: CMX Research
name: Richard Casey, MD
role: STUDY_DIRECTOR
References: